-
- Posts: 22
- Joined: Fri Dec 07, 2012 11:20 pm
API is similar to Boceprevir. C36H61N5O7S (contains ((1R,2S,5S)-3{N[....sulfonyl....cyclohexyl}amino)carbonyl...(1S)-1-.....(oxo)acetyl]pentyl......azabicyclo[3.1.0]hexan-2-carboxamide)
MM=707.4 Da
3-4 chiral centers?!
One diastereomer is well resolved with reversed HPLC and UPLC. But the possible conformers? Are they impacting on peak purity?
First we started with HPLC. ACE C18 column, MPA/MPB both containing MeOH/ACN/Phosphate buffer pH7. Gradient from 33% aqueous to 10% aqueous. In peak purity, autothreshold approach failed numerically and graphically (purity plot) for even the reference standard.
Then, redevelopment to UPLC. BEH Phenyl column, MPA Phosphate buffer pH7, MPB MeOH/Phosphate buffer pH 7, gradient from 40% to 10% aqueous. In peak purity, autothreshold approach passed numerically but purity plot present a "impure" zone at the ascending part of main peak even for the reference standard.
All requirements for correct peak purity evaluation were satisfied.
In both method, diluent was 0.01% TFA in MeOH. This is critical to extract and dissolve API from tablets.
From some experiments, it is suspected to have conformers since when column temperature is increased peak purity passes. But higher temperature dramatically reduces the sensitivity for several other resolved impurities.
Different pHs (FA, NH4OH) in mobile phase decreases sensitivity.
Should we try chiral approach in reversed or normal phase? With which type of columns? Any other thoughts?
Many thanks,
Pedro